4BIO raises VC fund to take cell and gene therapies mainstream

4BIO Capital has raised $50 million (€45 million) to invest in advanced therapy startups. The specialist venture capital player plans to pump the money, plus another $100 million it hopes to add by the final close, into companies that are working to extend use of advanced therapies to major diseases such as diabetes and rheumatoid arthritis.

Continue reading on FierceBiotech

By MIT Sloan CDO
MIT Sloan CDO Profile Picture